SII-YFV / Serum Institute of India - LARVOL DELTA

A Study of SII Yellow Fever Vaccine to Compare Safety and Immunogenicity With STAMARIL (clinicaltrials.gov) - P3 | N=1824 | Completed | Sponsor: Serum Institute of India Pvt. Ltd. | Recruiting ➔ Completed

Trial completion

A Study of SII Yellow Fever Vaccine to Compare Safety and Immunogenicity With STAMARIL® In Healthy Infants (clinicaltrials.gov) - P3 | N=2216 | Recruiting | Sponsor: Serum Institute of India Pvt. Ltd. | Not yet recruiting ➔ Recruiting | Trial completion date: Aug 2024 ➔ Jan 2024

Enrollment open • Trial completion date

A Study of SII Yellow Fever Vaccine to Compare Safety and Immunogenicity With STAMARIL (clinicaltrials.gov) - P3 | N=1824 | Recruiting | Sponsor: Serum Institute of India Pvt. Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open

A phase I clinical study to assess safety and immunogenicity of yellow fever vaccine. (PubMed, NPJ Vaccines) - "This was a Phase I, open-label, randomized, controlled study where healthy adults received SII YFV intramuscularly (SII YFV IM), SII YFV subcutaneously (SII YFV SC) or STAMARIL (Sanofi-Pasteur) in 1:1:1 ratio. The new YFV was found safe and immunogenic by IM as well as SC routes. The vaccine can be tested in further phases of clinical studies."

Journal • P1 data • Infectious Disease